Carcinoma hemorrhagiectoides: case report of an uncommon presentation of cutaneous metastatic breast carcinoma.

Corrugated Purple Plaque on the Left Cheek: Answer

“…Histologically carcinoma hemorrhagiectoides presents with abundant tumor cells involving dermal blood vessels and/or lymphatics. [1][2][3] Carcinoma erysipelatoides clinically presents with sharply demarcated, erythematous patches or plaques and histologically with tumor cells in the lymphatics. Carcinoma telangiectoides clinically presents with erythematous patches with prominent telangiectasias and histologically with tumor cells infiltrating into the blood vessels.…”

“…Carcinoma telangiectoides clinically presents with erythematous patches with prominent telangiectasias and histologically with tumor cells infiltrating into the blood vessels. 2,3 Carcinoma hemorrhagiectoides has been associated with SDC and breast cancer. 2,3 SDC metastases are rare, and to date, this case represents only the eighth reported case of SDC with cutaneous metastases.…”

“…2,3 Carcinoma hemorrhagiectoides has been associated with SDC and breast cancer. 2,3 SDC metastases are rare, and to date, this case represents only the eighth reported case of SDC with cutaneous metastases. Cutaneous metastases to the head, neck, and chest have been previously reported.…”

“…Cutaneous metastases to the head, neck, and chest have been previously reported. [2][3][4] Unfortunately, there are no histological markers that can be used to distinguish between metastatic SDC and high-grade ductal breast adenocarcinoma, and therefore, the distinction relies on clinical history and presentation. 2 Angiosarcoma and Kaposi sarcoma (KS) can present as purplish red, indurated plaques and therefore should be included in the differential diagnosis for this patient.…”

“…Therefore, dermatologist's awareness of the presentations of the various cutaneous metastases, including carcinoma hemorrhagiectoides, is important, given that they may constitute a presentation of metastatic cancer or reflect worsening metastatic burden of disease, as in this case. [2][3][4] Given our patient's disease progression despite receptor-targeted therapy, she has enrolled in a clinical trial.…”